BriaCell Therapeutics Corp.
BCTXW · NASDAQ
7/31/2025 | 7/31/2024 | 7/31/2023 | 7/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | -3.33 | -0.00 |
| FCF Yield | -171,154.32% | -114,802.45% | -60.81% | -27.98% |
| EV / EBITDA | 0.39 | 0.18 | -0.65 | -0.11 |
| Quality | ||||
| ROIC | -154.97% | 2,064.84% | -91.23% | -36.75% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.06 | 4.89 | 1.17 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -14.59% | -3.53% | -90.20% | -61.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.39 | 0.18 | 0.78 | 1.21 |
| Interest Coverage | -735.70 | 0.00 | 0.00 | -15,616.96 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -11,142.50 | -31,693.39 | -20,017.80 | -8,723.10 |